Latest outbreak of campylobacteriosis in Midwest is linked to unpasteurized product. The U.S. Food and Drug Administration, along with several state agencies, is alerting consumers to an outbreak of campylobacteriosis associated with drinking raw milk. At least 12 confirmed illnesses have been recently reported in Michigan. Symptoms of campylobacteriosis include diarrhea, abdominal pain and... »
Undiagnosed Diabetes Patients May Also Have Undiagnosed Kidney Disease
Millions of Americans may have chronic kidney disease (CKD) and not know it, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). “Our research indicates that much of the CKD burden in the United States is in persons with prediabetes and undiagnosed diabetes, who... »
Depression Among Low Income Latinos
A new, small study of low-income, depressed Latinos finds that those who stigmatize mental illness are less likely than others are to take medication, keep scheduled appointments and control their condition. The findings could help physicians develop a series of question to identity patients who might especially be resistant to care and then help... »
Community-Acquired MRSA’s Increasing Prevalence in Pediatric Patients
Once considered a hospital anomaly, community-acquired infections with drug-resistant strains of the bacterium Staphylococcus aureus now turn up regularly among children hospitalized in the intensive-care unit, according to research from the Johns Hopkins Children’s Center. The Johns Hopkins Children’s team’s findings, to be published in the April issue of the journal Emerging Infectious Diseases,... »
Xifaxan Approved by FDA for Patients with Liver Disease
The U.S. Food and Drug Administration (FDA) today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease. This is a new use for Xifaxan (rifaximin), a drug that has been approved for the treatment of traveler’s diarrhea. Hepatic encephalopathy... »
Zocor May Increase Muscle Injury Risk
The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg. Although muscle injury (called myopathy) is a known side effect with all statins, today’s warning highlights the greater risk of developing muscle injury, including rhabdomyolysis,... »